What it is
Zilucoplan is a small synthetic peptide — 15 amino acids, closed into a ring — that blocks complement protein C5. The Zilbrysq label calls it "a 15 amino-acid, synthetic macrocyclic peptide" and gives its free-acid formula as C172H278N24O55 at 3,562.23 daltons. Its chemical name shows that several residues are not among the 20 standard amino acids (N-methyl-aspartate, tert-leucine, 7-azatryptophan); at about 3.6 kDa it is a small molecule by protein standards.
| Property | Value | Source |
|---|---|---|
| Length | 15 amino acids, macrocyclic | Label section 11 |
| Formula (free acid) | C172H278N24O55 | Label; PubChem CID 133083018 |
| Molecular weight | 3,562.23 Da | Label |
| Target | Complement C5 | Label section 12.1 |
| Route | Subcutaneous, once daily, prefilled syringe | Label section 2 |
How it acts. Complement is a chain of blood proteins that, once triggered, ends in a pore-forming complex (C5b-9) that damages cell membranes. In myasthenia gravis, antibodies against the acetylcholine receptor trigger it at the junction where nerve meets muscle. The label states that zilucoplan "binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9" — and, in the same section, that "the precise mechanism by which zilucoplan exerts its therapeutic effect in generalized myasthenia gravis is unknown".
The library's other peptide complement drug acts one step earlier: pegcetacoplan blocks C3.
What the trial showed
The approval rests on one 12-week randomised, double-blind, placebo-controlled trial, RAISE (NCT04115293), described in the label's section 14. It enrolled 174 adults with AChR-antibody-positive generalized myasthenia gravis (MGFA class II–IV, MG-ADL score 6 or more), who kept their existing treatments at stable doses — about 85% were on cholinesterase inhibitors, 63% on steroids and 51% on non-steroidal immunosuppressants. Mean age was 53 and mean time since diagnosis 9 years.
| End point at week 12 | Zilucoplan (n = 86) | Placebo (n = 88) | Difference (95% CI) |
|---|---|---|---|
| MG-ADL total score (0–24), change | −4.39 | −2.30 | −2.09 (−3.24 to −0.95), P < 0.001 |
| QMG total score, change | −6.19 | −3.25 | −2.94 (−4.39 to −1.49), P < 0.001 |
| ≥3-point MG-ADL improvement | 73.1% | 46.1% | P < 0.001 |
| ≥5-point QMG improvement | 58% | 33% | P = 0.0012 |
The placebo arm improved too — by 2.3 points on a scale where the average starting score was 10.6 — which is why the between-group difference, about two points, is the figure to read.
What is not established by this record: results beyond the 12-week controlled period (the label's safety data note 87 patients exposed for at least a year, not a controlled comparison), use in antibody-negative or MuSK-antibody myasthenia, and any head-to-head comparison with other C5 blockers.
Risks the label lists
| Reaction (Study 1) | Zilucoplan | Placebo |
|---|---|---|
| Injection-site reactions | 29% | 16% |
| Upper respiratory tract infections | 14% | 7% |
| Diarrhoea | 11% | 2% |
| Urinary tract infection | 8% | 5% |
| Lipase increased | 7% | 0% |
| Amylase increased | 5% | 1% |
- Boxed warning: serious meningococcal infections, which "may become rapidly life-threatening or fatal". The label requires vaccination against serogroups A, C, W, Y and B at least two weeks before the first dose unless delaying treatment is riskier.
- REMS: Zilbrysq is available only through a restricted programme in which prescribers must enrol and counsel patients about meningococcal risk.
- Pancreas: pancreatitis and pancreatic cysts have been reported; the label asks for baseline amylase and lipase and for the drug to be stopped while pancreatitis is suspected.
Where it stands
Drugs@FDA lists Zilbrysq under NDA 216834, held by UCB, original approval 17 October 2023, as a prescription solution in three strengths. The label gives a weight-band dose rather than a per-kilogram one: 16.6 mg (under 56 kg), 23 mg (56 to under 77 kg) and 32.4 mg (77 kg and above), each a daily subcutaneous injection — a scheme built around the 0.3 mg/kg dose tested in RAISE. The DailyMed record on 2026-11-20 was version 13, published 5 February 2026.
Sources opened 2026-11-20: Zilbrysq label (openFDA full text, effective 2026-02-03: sections 1, 2, 5, 6 incl. Table 2, 11, 12.1, 14 incl. Table 3); DailyMed SPL listing (version 13, 2026-02-05); Drugs@FDA record for NDA 216834; PubChem CID 133083018; PubMed E-utilities and ClinicalTrials.gov API v2 counts.
